Valsts: Singapūra
Valoda: angļu
Klimata pārmaiņas: HSA (Health Sciences Authority)
Losartan Potassium
ORGANON SINGAPORE PTE. LTD.
C09CA01
100 mg
TABLET, COATED
Losartan Potassium 100 mg
ORAL
Prescription Only
Organon Pharma (UK) Limited
ACTIVE
2007-03-23
PRODUCT CIRCULAR SG-OG0954(G)-T-102021 LORTAN Tablet (losartan potassium) USE IN PREGNANCY Drugs that act directly on the renin-angiotensin system can cause injury and even death in the developing fetus. When pregnancy is detected, discontinue LORTAN as soon as possible. I. THERAPEUTIC CLASS LORTAN (losartan potassium), the first of a new class of antihypertensives, is an angiotensin II receptor (type AT 1 ) antagonist. LORTAN also provides a reduction in the risk of stroke in hypertensive patients with left ventricular hypertrophy and renal protection for type 2 diabetic patients with proteinuria. II. INDICATIONS Hypertension LORTAN is indicated for the treatment of hypertension. Hypertensive Patients with Left Ventricular Hypertrophy LORTAN is indicated for the reduction in the risk of stroke in hypertensive patients with left ventricular hypertrophy (see RACE). Renal Protection in Type 2 Diabetic Patients with Proteinuria LORTAN is indicated to delay the progression of renal disease as measured by a reduction in the incidence of doubling of serum creatinine and end stage renal disease (need for dialysis or renal transplantation), and to reduce proteinuria. III. DOSAGE AND ADMINISTRATION LORTAN may be administered with or without food. LORTAN may be administered with other antihypertensive agents. Hypertension The usual starting and maintenance dose is 50 mg once daily for most patients. The maximal antihypertensive effect is attained 3-6 weeks after initiation of therapy. Some patients may receive an additional benefit by increasing the dose to 100 mg once daily. For patients with intravascular volume-depletion (e.g., those treated with high-dose diuretics), a starting dose of 25 mg once daily should be considered (see PRECAUTIONS). No initial dosage adjustment is necessary for elderly patients up to 75 years of age, or for patients with mild renal impairment. For patients above 75 years of age, patients with moderate to severe renal impairment and patients on dialysis, a lower starting dose of 25 mg is recomm Izlasiet visu dokumentu